Sysmex Inostics
Agathe Lamik has a background in biochemistry, having studied at Freie Universität Berlin. Agathe has worked in various roles in different companies such as Sysmex Inostics, BIOTECON Diagnostics GmbH, and Verlag Wilhelm Ernst & Sohn. Agathe's experience ranges from being a scientist in research and innovation to working as a lab worker and freelancer.
This person is not in any offices
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.